FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1439122904> ?p ?o ?g. }

• W1439122904 abstract "Background Although a number of cancer chemopreventive agents have now been evaluated in phase II and phase III clinical trials that assess their efficacy and tolerability in both high risk and general populations, few have shown clear efficacy and uptake of approved agents has been disappointingly low. Therefore, chemopreventive agents should undergo rigorous screening prior to clinical trial evaluation in order to improve the selection of suitable agents for testing in large, expensive multi-center phase III trials. The aim of this study is to develop a descriptive method for prioritizing candidate agents for further development. Methods This framework was developed through a systematic literature review of Pubmed/Medline, Embase and The Cochrane Library. A semi-quantitative assessment focusing on efficacy and toxicity/tolerability was established based on expert input. Data from clinical trials, cancer epidemiological, observational and preclinical studies, including in vivo and in vitro basic research, was used to retrospectively evaluate the clinical application and effectiveness of cancer chemopreventive agents. Two chemopreventive agents with either a positive (aromatase inhibitors (AIs) for breast cancer) or negative (selenium for lung cancer) phase III clinical trial outcome were subsequently evaluated to determine the usefulness of the framework. Results Chemopreventive agents must reduce or reverse the process of carcinogenesis in normal or pre-malignant tissue with minimal toxicity. Evaluation of efficacy included data from preclinical and animal models, epidemiological studies, and clinical trials (both early phase trials in the organ of interest as well as secondary endpoints from other relevant studies). Agent suitability evaluation included assessment of toxicities, tolerability, and agent specific attributes (PK/PD, bioavailability, dosing, etc.). Examination of selenium and AI historical data in these categories revealed strong concordance with phase III outcomes. The detailed descriptive evaluation of the agents will be presented. Conclusion This framework provides a descriptive paradigm for cancer chemopreventive agent evaluation through systematic and rigorous interrogation. Thorough, standardized evaluation of all available preclinical, epidemiological, and clinical data should be strongly encouraged to better inform the investments required for clinical trials. Citation Format: Naomi Walsh, David S. Alberts, Powel Brown, Paul Limburg, Mark Sherman, Eva Szabo. Framework for clinical evaluation of chemopreventive agents: Defining criteria for future assessment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4662. doi:10.1158/1538-7445.AM2015-4662" @default.
• W1439122904 created "2016-06-24" @default.
• W1439122904 creator A5009475462 @default.
• W1439122904 creator A5020366697 @default.
• W1439122904 creator A5029541691 @default.
• W1439122904 creator A5032059107 @default.
• W1439122904 creator A5069756775 @default.
• W1439122904 creator A5076159971 @default.
• W1439122904 date "2015-08-01" @default.
• W1439122904 modified "2023-09-26" @default.
• W1439122904 title "Abstract 4662: Framework for clinical evaluation of chemopreventive agents: Defining criteria for future assessment" @default.
• W1439122904 doi "https://doi.org/10.1158/1538-7445.am2015-4662" @default.
• W1439122904 hasPublicationYear "2015" @default.
• W1439122904 type Work @default.
• W1439122904 sameAs 1439122904 @default.
• W1439122904 citedByCount "0" @default.
• W1439122904 crossrefType "proceedings-article" @default.
• W1439122904 hasAuthorship W1439122904A5009475462 @default.
• W1439122904 hasAuthorship W1439122904A5020366697 @default.
• W1439122904 hasAuthorship W1439122904A5029541691 @default.
• W1439122904 hasAuthorship W1439122904A5032059107 @default.
• W1439122904 hasAuthorship W1439122904A5069756775 @default.
• W1439122904 hasAuthorship W1439122904A5076159971 @default.
• W1439122904 hasConcept C121608353 @default.
• W1439122904 hasConcept C126322002 @default.
• W1439122904 hasConcept C143998085 @default.
• W1439122904 hasConcept C177713679 @default.
• W1439122904 hasConcept C197934379 @default.
• W1439122904 hasConcept C23131810 @default.
• W1439122904 hasConcept C2778375690 @default.
• W1439122904 hasConcept C530470458 @default.
• W1439122904 hasConcept C535046627 @default.
• W1439122904 hasConcept C71924100 @default.
• W1439122904 hasConcept C98274493 @default.
• W1439122904 hasConceptScore W1439122904C121608353 @default.
• W1439122904 hasConceptScore W1439122904C126322002 @default.
• W1439122904 hasConceptScore W1439122904C143998085 @default.
• W1439122904 hasConceptScore W1439122904C177713679 @default.
• W1439122904 hasConceptScore W1439122904C197934379 @default.
• W1439122904 hasConceptScore W1439122904C23131810 @default.
• W1439122904 hasConceptScore W1439122904C2778375690 @default.
• W1439122904 hasConceptScore W1439122904C530470458 @default.
• W1439122904 hasConceptScore W1439122904C535046627 @default.
• W1439122904 hasConceptScore W1439122904C71924100 @default.
• W1439122904 hasConceptScore W1439122904C98274493 @default.
• W1439122904 hasLocation W14391229041 @default.
• W1439122904 hasOpenAccess W1439122904 @default.
• W1439122904 hasPrimaryLocation W14391229041 @default.
• W1439122904 hasRelatedWork W10691706 @default.
• W1439122904 hasRelatedWork W2023211058 @default.
• W1439122904 hasRelatedWork W2071209217 @default.
• W1439122904 hasRelatedWork W2096688198 @default.
• W1439122904 hasRelatedWork W2100251566 @default.
• W1439122904 hasRelatedWork W2161756110 @default.
• W1439122904 hasRelatedWork W2166499722 @default.
• W1439122904 hasRelatedWork W2184431203 @default.
• W1439122904 hasRelatedWork W2259194869 @default.
• W1439122904 hasRelatedWork W2322100955 @default.
• W1439122904 hasRelatedWork W2394432079 @default.
• W1439122904 hasRelatedWork W2412277735 @default.
• W1439122904 hasRelatedWork W2412646424 @default.
• W1439122904 hasRelatedWork W2413923373 @default.
• W1439122904 hasRelatedWork W2942860247 @default.
• W1439122904 hasRelatedWork W3157488309 @default.
• W1439122904 hasRelatedWork W3162595824 @default.
• W1439122904 hasRelatedWork W5407214 @default.
• W1439122904 hasRelatedWork W585537879 @default.
• W1439122904 hasRelatedWork W2465310684 @default.
• W1439122904 isParatext "false" @default.
• W1439122904 isRetracted "false" @default.
• W1439122904 magId "1439122904" @default.
• W1439122904 workType "article" @default.